Detector-C: A Blood-based IVD with High Sensitivity and Specificity for Early Detection and Screening of Colorectal Cancer

2010 ◽  
Vol 48 (08) ◽  
Author(s):  
A Rosenthal ◽  
H Köppen ◽  
R Musikowski ◽  
R Schwanitz ◽  
J Behrendt ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Early Detection ◽  
Sensitivity And Specificity ◽  
High Sensitivity

scholarly journals Colorectal Cancer Blood-Based Biomarkers

2017 ◽  
Vol 2017 ◽  
pp. 1-11 ◽  
Author(s):  
Nina Hauptman ◽  
Damjan Glavač
Keyword(s):  
Colorectal Cancer ◽  
Early Detection ◽  
Sensitivity And Specificity ◽  
Screening Test ◽  
Early Stage ◽  
High Sensitivity ◽  
Recurrence Risk ◽  
Liquid Biopsies ◽  
Mortality And Morbidity ◽  
Potential Biomarkers

Mortality and morbidity associated with colorectal cancer (CRC) are increasing globally, partly due to lack of early detection of the disease. The screening is usually performed with colonoscopy, which is invasive and unpleasant, discouraging participation in the screening. As a source of noninvasive and easily accessible biomarkers, liquid biopsies are emerging. Blood-based biomarkers have the potential as diagnostic and prognostic tool in CRC. Early stage detection of CRC with high sensitivity and specificity would likely lead to higher participation in the screening test. It would also improve the prognosis of the disease and improve the recurrence risk. In this review, we summarize the potential biomarkers for early detection and monitoring of CRC.

Detector-C: A blood-based IVD with high sensitivity and specificity for early detection of colorectal cancer.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3580-3580
Author(s):  
A. Rosenthal ◽  
D. Nuernberg ◽  
M. Pross ◽  
J. Pertschy ◽  
P. Nartschik ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Early Detection ◽  
Sensitivity And Specificity ◽  
High Sensitivity

scholarly journals Blood-Based Detection of Colorectal Cancer Using Cancer-Specific DNA Methylation Markers

Diagnostics ◽  
2020 ◽  
Vol 11 (1) ◽  
pp. 51
Author(s):  
Nam-Yun Cho ◽  
Ji-Won Park ◽  
Xianyu Wen ◽  
Yun-Joo Shin ◽  
Jun-Kyu Kang ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Dna Methylation ◽  
Sensitivity And Specificity ◽  
Stage Iv ◽  
High Sensitivity ◽  
Liquid Biopsies ◽  
Blood Leukocytes ◽  
Marker Panel ◽  
A Genome ◽  
Methylight Assay

Cancer tissues have characteristic DNA methylation profiles compared with their corresponding normal tissues that can be utilized for cancer diagnosis with liquid biopsy. Using a genome-scale DNA methylation approach, we sought to identify a panel of DNA methylation markers specific for cell-free DNA (cfDNA) from patients with colorectal cancer (CRC). By comparing DNA methylomes between CRC and normal mucosal tissues or blood leukocytes, we identified eight cancer-specific methylated loci (ADGRB1, ANKRD13, FAM123A, GLI3, PCDHG, PPP1R16B, SLIT3, and TMEM90B) and developed a five-marker panel (FAM123A, GLI3, PPP1R16B, SLIT3, and TMEM90B) that detected CRC in liquid biopsies with a high sensitivity and specificity with a droplet digital MethyLight assay. In a set of cfDNA samples from CRC patients (n = 117) and healthy volunteers (n = 60), a panel of five markers on the platform of the droplet digital MethyLight assay detected stages I–III and stage IV CRCs with sensitivities of 45.9% and 95.7%, respectively, and a specificity of 95.0%. The number of detected markers was correlated with the cancer stage, perineural invasion, lymphatic emboli, and venous invasion. Our five-marker panel with the droplet digital MethyLight assay showed a high sensitivity and specificity for the detection of CRC with cfDNA samples from patients with metastatic CRC.

scholarly journals Identification of an epigenetic biomarker panel with high sensitivity and specificity for colorectal cancer and adenomas

2011 ◽  
Vol 10 (1) ◽  
pp. 85 ◽  
Author(s):  
Guro E Lind ◽  
Stine A Danielsen ◽  
Terje Ahlquist ◽  
Marianne A Merok ◽  
Kim Andresen ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Sensitivity And Specificity ◽  
High Sensitivity ◽  
Biomarker Panel ◽  
Epigenetic Biomarker

scholarly journals Multiplex methylated DNA testing in plasma with high sensitivity and specificity for colorectal cancer screening

2019 ◽  
Vol 8 (12) ◽  
pp. 5619-5628 ◽  
Author(s):  
Guodong Zhao ◽  
Hui Li ◽  
Zixuan Yang ◽  
Zhenzhen Wang ◽  
Manqiu Xu ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Screening ◽  
Colorectal Cancer Screening ◽  
Sensitivity And Specificity ◽  
High Sensitivity ◽  
Dna Testing ◽  
Methylated Dna

Potential Use of Biomarkers to Augment Clinical Decisions for the Early Detection of Breast Cancer

2014 ◽  
Vol 10 (02) ◽  
pp. 103 ◽  
Author(s):  
Alan B Hollingsworth ◽  
David E Reese ◽  
◽  
Keyword(s):  
Breast Cancer ◽  
Early Detection ◽  
Sensitivity And Specificity ◽  
Cancer Detection ◽  
Survival Rates ◽  
High Sensitivity ◽  
Standard Of Care ◽  
Serum Biomarkers ◽  
Breast Cancer Detection ◽  
Breast Cancers

Breast cancer remains a significant worldwide health problem, despite the fact that early detection is associated with excellent survival rates. Currently, a substantial proportion of breast cancers are not detected using routine screening. Therefore, there is a need to identify a technology that can improve the precision and accuracy of early breast cancer detection. Biomarkers are attractive in that they can potentially detect early cancers with high sensitivity, while distinguishing between benign disease and invasive cancers. Many commonly used serum biomarkers have limited use in screening assays for breast cancer as single agents due to the heterogeneous nature of breast cancer. However, the use of protein panels that detect multiple serum biomarkers offer the potential for enhanced sensitivity and specificity in a clinical setting. Recently, a serum biomarker test comprising five serum biomarkers for breast cancer was clinically validated and showed high sensitivity and specificity. Additional panels have been developed that combine serum protein biomarkers (SPB) and tumor-associated autoantibodies (TAb) to further enhance the clinical utility of the assay. Serum biomarkers are currently not the standard of care and are not recommended in any detection guidelines. However, tumor biomarkers are used in the breast cancer setting to determine the course of care. The purpose of this article is to review recent advances in SPB, TAb, and biomarkers used in breast cancer detection to provide a perspective on how these technologies may offer benefit when combined with current imaging modalities.

Sign in / Sign up

Export Citation Format

Share Document